Johnson & Johnson reported Q1 2026 adjusted EPS of $2.70 on reported sales of $24.1 Billion, reflecting 9.9% top-line growth but lower net earnings year over year. The release struck a broadly constructive tone with raised 2026 guidance; stock reaction will depend on broader market and after-hours movement.
About Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) is a global healthcare company focused on pharmaceuticals (Innovative Medicine) and medical devices (MedTech), founded in 1886 and headquartered in New Brunswick, New Jersey. The company develops, manufactures, and markets products that prevent, treat, and cure complex diseases across oncology, immunology, neuroscience, cardiovascular, surgery, and vision care.
As of recent filings, J&J employs approximately 140,000 people worldwide and positions itself as a diversified healthcare innovator with a robust late‑stage pipeline. While the exact market cap and P/E ratio are not given in the Q1 release, J&J is typically valued among the largest global healthcare companies, supported by consistent dividend payments and investment‑grade credit ratings. The quarter’s results highlight growing contributions from oncology and neuroscience therapies as well as cardiovascular MedTech, underpinned by new product approvals such as ICOTYDE, VARIPULSE Pro, and TECNIS PureSee.
Top Financial Highlights
- Q1 2026 reported sales were $24.1 Billion, up 9.9% year over year, with operational growth of 6.4% and adjusted operational growth of 5.3%.
- Q1 2026 net earnings were $5.24 Billion, down 52.4% versus Q1 2025, primarily reflecting prior-year one-time items.
- Diluted EPS came in at $2.14, a 52.9% decline from $4.54 in the prior-year quarter.
- Adjusted net earnings were $6.61 Billion, a modest 1.4% decline year over year.
- Adjusted diluted EPS was $2.70, down 2.5% from $2.77 in Q1 2025.
- Free cash flow for Q1 2026 was estimated at roughly $1.5 Billion, versus $3.38 Billion a year earlier.
- Innovative Medicine segment sales reached $15.43 Billion, growing 11.2% reported and 7.4% operationally, driven by oncology and immunology brands.
- MedTech segment sales were $8.64 Billion, up 7.7% reported and 4.6% operationally, led by electrophysiology, Abiomed, Shockwave, and trauma.
- U.S. sales were $13.33 Billion, an 8.3% increase, while International sales rose 11.9% to $10.73 Billion.
- Worldwide adjusted operational sales growth was 5.3%, reflecting strength across both segments after excluding currency and M&A effects.
- Management now guides 2026 estimated reported sales to $100.3–$101.3 Billion, with a midpoint of $100.8 Billion, implying 7.0% growth.
- Adjusted EPS guidance was raised to $11.45–$11.65 (midpoint $11.55), equating to about 7.1% growth at the midpoint.
- Innovative Medicine growth was helped by products such as DARZALEX, CARVYKTI, ERLEADA, RYBREVANT/LAZCLUZE, TREMFYA, and SPRAVATO, partially offset by STELARA and IMBRUVICA headwinds.
- MedTech saw continued momentum in cardiovascular (including VARIPULSE platform and electrophysiology) and orthopaedics trauma franchises.
Beat or Miss?
Analyst consensus heading into the print called for Q1 2026 EPS of roughly $2.67–$2.68 per share and revenue around $23.4–$23.6 Billion. Johnson & Johnson’s results therefore reflected a top-line beat and a slight EPS beat on an adjusted basis.
| Metric | Reported (Q1 2026) | Difference/Analysis |
| Revenue | $24.1B | Above consensus expectations of about $23.4–$23.6B; solid beat with 9.9% YoY growth. |
| GAAP EPS (diluted) | $2.14 | Down sharply YoY due to prior-year items; below adjusted performance and not directly comparable to consensus. |
| Adjusted EPS (diluted) | $2.70 | Slightly above consensus around $2.67–$2.68, representing a modest earnings beat. |
| Operational Sales Growth | 6.4% | In line with management’s full-year growth algorithm and supportive of raised 2026 guidance. |
What Leadership Is Saying?
“Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact. The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game‑changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe. These advancements have the potential to transform patient outcomes and create sustainable, long‑term value for shareholders.” – Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson
“Our first‑quarter results, including 6.4% operational sales growth and adjusted EPS of $2.70, give us the confidence to raise our full‑year 2026 sales and adjusted EPS guidance. We remain focused on disciplined capital allocation, investing behind our highest‑growth platforms while managing margins through targeted restructuring in Orthopaedics and Surgery to support sustainable, profitable growth.” – Joseph Wolk, Executive Vice President and Chief Financial Officer
Historical Performance
Johnson & Johnson YoY (Q1 2026 vs Q1 2025)
| Category | Q1 2026 | Q1 2025 | Change (%) |
| Revenue (Sales) | $24,062M | $21,893M | +9.9% reported; +6.4% operational. |
| Net Earnings | $5,235M | $10,999M | -52.4%, reflecting tough comparison versus prior-year gains/special items. |
| Diluted EPS | $2.14 | $4.54 | -52.9% year over year on a GAAP basis. |
| Adjusted Net Earnings | $6,614M | $6,706M | -1.4%, showing largely stable underlying profitability. |
| Adjusted EPS | $2.70 | $2.77 | -2.5%, modest decline against a strong prior-year base. |
How the Market Reacted?
Given the combination of a revenue beat, slightly better-than-expected adjusted EPS, and a raise to full-year 2026 sales and EPS guidance, the underlying tone of the report is constructive and mildly bullish. However, the sharp decline in GAAP net earnings versus the prior year and softer free cash flow could temper enthusiasm, especially in a market focused on cash generation. Actual intraday and after-hours stock performance will depend on broader sector sentiment, interest-rate expectations, and investor interpretation of pipeline and legal overhangs.
